Chemomab Therapeutics Ltd.
CMMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $32,494 | $5,992 | $36,414 | $71,577 |
| - Cash | $6,071 | $9,292 | $13,519 | $14,686 |
| + Debt | $324 | $392 | $214 | $343 |
| Enterprise Value | $26,747 | -$2,908 | $23,109 | $57,234 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$53 | -$67 | -$58 | -$34 |
| % Margin | – | – | – | – |
| EBITDA | -$13,958 | -$25,392 | -$28,475 | -$12,333 |
| % Margin | – | – | – | – |
| Net Income | -$13,945 | -$24,221 | -$27,646 | -$12,478 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.12 | -8.22 | -9.68 | -4.8 |
| % Growth | 62% | 15.1% | -101.7% | – |
| Operating Cash Flow | -$15,459 | -$23,611 | -$20,370 | -$12,374 |
| Capital Expenditures | $0 | -$3 | -$68 | -$239 |
| Free Cash Flow | -$15,386 | -$23,614 | -$20,438 | -$12,613 |